Biotech's Next Big Thing: Aegerion

Aegerion and its cholesterol drug will be biotech's big thing in the coming week, says Adam Feuerstein, Sr. Columnist for TheStreet.
By Gregg Greenberg ,

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

Loading ...